Literature DB >> 30241689

Recommendations on non-Pharmacological Treatment in Chronic Obstructive Pulmonary Disease From the Spanish COPD Guidelines (GesEPOC 2017).

Eulogio Pleguezuelos1, Elena Gimeno-Santos2, Carmen Hernández3, María Del Carmen Mata4, Leopoldo Palacios5, Pascual Piñera6, Jesús Molina7, Eusebi Chiner8, Marc Miravitlles9.   

Abstract

Non-pharmacological treatment is essential in patients with chronic obstructive pulmonary disease (COPD), but this treatment is sometimes not given the importance it deserves. Patients diagnosed with COPD should benefit from comprehensive care services. These services comprise a protocolized set of actions aimed at covering the health needs of the patient, taking into account their environment and circumstances. Pulmonary rehabilitation is one of the essential components of non-pharmacological treatment in comprehensive COPD care services. In the Spanish COPD Guidelines (GesEPOC) 2017, we provided a systematic report of the scientific evidence for pulmonary rehabilitation programs in acute and stable phase disease. Another important issue in the non-pharmacological treatment of COPD is physical activity, and the most essential considerations regarding prescription are described in the GesEPOC guidelines, along with a review of the most effective strategies to ensure adherence. GesEPOC 2017 aims to underline the importance of non-pharmacological treatment as a co-adjuvant to pharmacological treatment.
Copyright © 2018 SEPAR. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Actividad física; Autocuidado; Chronic obstructive pulmonary disease; Enfermedad pulmonar obstructiva crónica; Integrated care service; Physical activity; Pulmonary rehabilitation; Rehabilitación pulmonar; Self-care; Servicio de atención integrada

Mesh:

Year:  2018        PMID: 30241689     DOI: 10.1016/j.arbres.2018.06.001

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


  6 in total

1.  Easy to Perform Physical Performance Tests to Identify COPD Patients with Low Physical Activity in Clinical Practice.

Authors:  Zinka Matkovic; Neven Tudoric; Danijel Cvetko; Cristina Esquinas; Dario Rahelic; Marko Zarak; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-04-24

2.  B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Víctor Curull; Xuejie Wang; Mercé Mateu-Jiménez; Lara Pijuan; Xavier Duran; Liyun Qin; Alberto Rodríguez-Fuster; Rafael Aguiló; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

3.  Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Víctor Curull; Xuejie Wang; Liyun Qin; Mercé Mateu-Jiménez; Xavier Duran; Lara Pijuan; Alberto Rodríguez-Fuster; Rafael Aguiló Espases; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

4.  The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic.

Authors:  Eulogio Pleguezuelos; Amin Del Carmen; Eva Moreno; Pilar Ortega; Xavier Vila; Laura Ovejero; Mateu Serra-Prat; Elisabet Palomera; Manuel Vicente Garnacho-Castaño; Eduardo Loeb; Georgina Farago; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-23

5.  Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil.

Authors:  José R Jardim; Francisco Casas-Maldonado; Frederico Leon Arrabal Fernandes; Maria Vera Cruz de O Castellano; María Torres-Durán; Marc Miravitlles
Journal:  J Bras Pneumol       Date:  2021-05-31       Impact factor: 2.624

Review 6.  Air pollution and health prevention: A document of reflection.

Authors:  E Bouza; F Vargas; B Alcázar; T Álvarez; A Asensio; G Cruceta; D Gracia; J Guinea; M A Gil; C Linares; P Muñoz; P Pastor; M L Pedro-Botet; X Querol; J Tovar; I Urrutia; F Villar; E Palomo
Journal:  Rev Esp Quimioter       Date:  2022-03-11       Impact factor: 2.515

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.